Teva Pharmaceutical Industries reported a better than expected increase in second-quarter profit on Wednesday, helped by a 26 ...

Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

Reported EPS is $0.2429 EPS, expectations were $0.63. Operator: Hello, and welcome to the Teva Pharmaceutical Industries ...

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

Teva Pharmaceuticals swung to a second-quarter profit though narrowed its full-year adjusted earnings guidance. The Israeli based pharmaceutical company posted a second-quarter profit of $282 million, ...

We recently compiled a list of the 10 Firms Kick Off 2025 Trading in The Red. In this article, we are going to take a look at where Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) stands against ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) Despite news of losing the bid against Amneal Pharmaceuticals and having to remove incorrect patents for an inhaler product, shares of Teva ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Teva Pharmaceuticals(TEVA 0.45%) is the world's largest manufacturer of generic drugs. The company is going through numerous challenges at the moment, among them being the exit of former CEO ...